如何在需求高度未满足的超罕见癌症中开发新的全身治疗?以腺泡状软组织肉瘤为例
超罕见肿瘤年发病率不超过百万分之一,开发新药或为新适应症生成证据复杂且失败风险高。本文以欧盟每年新诊断约60人的腺泡状软组织肉瘤(ASPS)为例,说明超罕见肿瘤中充分证据生成的挑战,并探讨学术界、患者与倡导者、制药商和监管机构之间建设性合作以优化药物开发的可能途径。
要点
- 超罕见肿瘤年发病率不超过百万分之一,药物开发证据生成复杂且失败风险高。
- ASPS在欧盟每年新诊断约60人,是展示超罕见肿瘤开发挑战的范例。
- 本文由欧洲多方利益相关者撰写,提出通过建设性合作优化超罕见癌症药物开发的前进方向。
核心结论
- 本文提出通过学术界、患者与倡导者、制药商和监管机构之间的建设性合作,最终为超罕见癌症患者提供更好的选择。
研究设计与样本
- 本文为欧洲多方利益相关者撰写的评论文章,以腺泡状软组织肉瘤(ASPS)为例说明超罕见肿瘤中充分证据生成的挑战。
主要发现
- 超罕见肿瘤年发病率不超过百万分之一,开发新药或为新适应症生成证据复杂且失败风险高。
- ASPS在欧盟每年新诊断约60人,尽管可能对某类药物 relevant,但开发仍面临挑战。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Developing new drugs or generating evidence for existing drugs in new indications for ultra-rare cancers is complex and carries a high-risk of failure. This gets even harder in ultra-rare tumours, which have an annual incidence of 1 per 1,000,000 population or less. Here, we illustrate the problem of adequate evidence generation in ultra-rare tumours, using Alveolar Soft-Part Sarcomas (ASPS) - an ultra-rare sarcoma newly diagnosed in approximately 60 persons a year in the European Union - as an exemplar case showing challenges in development despite being potentially relevant for classes of agents. We discuss some possible approaches for addressing such challenges, especially focussing on constructive collaboration between academic groups, patients and advocates, drug manufacturers, and regulators to optimise drug development in ultra-rare cancers. This article, written by various European stakeholders, proposes a way forward to ultimately get better options for patients with ultra-rare cancers.
引用
- Stacchiotti S, Bouche G, Herold R, et al. How to develop new systemic treatments in ultra-rare cancers with high unmet needs? The case of alveolar soft-part sarcoma. Eur J Cancer. 2024. PMID: 38479120. doi:10.1016/j.ejca.2024.114003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。